= Emerging. More than 5 years before clinical availability. (24.37%, 2023)
= Expected to be clinically available in 1 to 4 years. (39.50%, 2023)
= Clinically available now. (36.13%, 2023)
MSACL 2023 : Lynch

MSACL 2023 Abstract

Self-Classified Topic Area(s): Practical Training > none > none

Podium Presentation in Colton on Thursday at 8:45 (Chair: TBA)

Pediatric Toxicology Testing Strategies: A Case-based Discussion

Kara Lynch
University of California, San Francisco

Kara Lynch, PhD, DABCC (Presenter)
University of California San Francisco

Presenter Bio: Dr. Kara Lynch is a Professor of Laboratory Medicine at the University of California San Francisco, Co-Director of the Core Laboratory at Zuckerberg San Francisco General Hospital and Chemistry Director at UCSF Benioff Children’s Hospital Oakland. She is the co-director of the COMACC-accredited Clinical Chemistry Fellowship Program at UCSF. Her laboratory conducts studies aimed at identifying and quantifying endogenous and exogenous small molecules in biological specimens using novel diagnostic technologies, such as high resolution mass spectrometry, ion mobility mass spectrometry, ambient ionization mass spectrometry and biolayer interferometry. Her lab is involved in translational research studies evaluating the clinical utility of novel biomarkers or biomarker panels to diagnosis, treat and monitor disease. The methods developed in her laboratory are used to investigate perturbations in metabolic pathways caused by disease and drug use and translate the results into information that can be used in clinical practice.



Drug testing typically follows a one-size fits all approach that falls short of meeting the needs of some of our most vulnerable patients, children. The coexistence of the opioid epidemic and COVID-19 pandemic has exacerbated the rise in pediatric drug exposures from unintentional exposures in early childhood to intentional use in early adolescents. Results from immunoassay-based testing that are non-specific, insensitive, and far from comprehensive can lead to unintended consequences for children and their families. The need to evaluate and study alternative mass-spectrometry based approaches to drug testing in pediatric patients is essential. This session will explain the fundamentals and highlight the advantages and disadvantages of alternative approaches to pediatric toxicology testing to identify acute exposure. Key concepts will be taught through a case-based presentation.

Take Home Pearls:
After hearing this talk attendees will be able to 1) describe the advantages and disadvantages of different analytical approaches for the detection of pediatric drug exposure, 2) interpret clinical symptoms and analytical results associated with common pediatric drug exposures and 3) compare and contrast adult and pediatric testing approaches and needs.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: